19 Dec 2023 by admin in UncategorizedComments Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
13 Dec 2023 by admin in UncategorizedComments Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan- inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis
06 Dec 2023 by admin in UncategorizedComments Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
06 Dec 2023 by admin in UncategorizedComments Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC
05 Dec 2023 by admin in UncategorizedComments Adcentrx Announces Extension of Series A+ Financing to $51 Million
05 Dec 2023 by admin in UncategorizedComments Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
04 Dec 2023 by admin in UncategorizedComments Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
15 Nov 2023 by admin in UncategorizedComments ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
19 Oct 2023 by admin in UncategorizedComments Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to form Sail
02 Oct 2023 by admin in UncategorizedComments Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
19 Sep 2023 by admin in UncategorizedComments Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
12 Sep 2023 by admin in UncategorizedComments Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 and Preclinical Studies in Autoimmune Skin Disease Models from Collaboration with University of Lübeck at the 29th International Complement Workshop (ICW 2023)
07 Sep 2023 by admin in UncategorizedComments NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
05 Sep 2023 by admin in UncategorizedComments Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb
04 Sep 2023 by admin in UncategorizedComments Crescendo Biologics Wins Significant European Patent Office Ruling Related to the Engineering of Immunoglobulin Therapeutics
18 Aug 2023 by admin in UncategorizedComments Eluminex Biosciences Completes Series B+ Financing, Raising More Than $50 M in 2023
14 Aug 2023 by admin in UncategorizedComments Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
10 Aug 2023 by admin in UncategorizedComments Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact
24 Jul 2023 by admin in UncategorizedComments Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours
17 Jul 2023 by admin in UncategorizedComments Alebund Achieved First Patient Enrolment for AP301 Pivotal Phase 3 Clinical Trial and Successfully Held Investigator Meeting in Beijing
11 Jul 2023 by admin in UncategorizedComments Adicet Announces Appointment of Katie Peng to the Board of Directors
16 May 2023 by admin in UncategorizedComments Eluminex Biosciences Receives Scientific Recognition for its Recombinant Human Collagen (rhCIII) Biosynthetic Cornea (EB- 301) Program to Treat Corneal Blindness
09 May 2023 by admin in UncategorizedComments Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies
27 Apr 2023 by admin in UncategorizedComments Crescendo Biologics appoints Angus Hone as Chief Financial Officer
12 Apr 2023 by admin in UncategorizedComments Alebund Pharmaceuticals Closes Nearly RMB 200 Million Pre-C Round Financing and Secures RMB 800 Million Syndicated Loan Credit
17 Mar 2023 by admin in UncategorizedComments China’s NMPA Clears Phase 3 IND Application for Alebund Pharmaceutical’s AP301, a New-generation Iron-based Phosphate Binder, to Treat Hyperphosphatemia in Dialysis Patients
28 Feb 2023 by admin in UncategorizedComments Oricell Closes $45M Series B1 Financing to Expand Development of Key Products
28 Feb 2023 by admin in UncategorizedComments Eluminex Biosciences Closes $40+ Million Series B Financing
14 Feb 2023 by admin in UncategorizedComments Eluminex Announces Completion of Enrollment in Part A of the CLARITY Study
31 Jan 2023 by admin in UncategorizedComments Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR- 017 in the Treatment of RRMM
31 Jan 2023 by admin in UncategorizedComments Crescendo Biologics is category winner for Biopharma and Vaccines in 2023 UK DIT Life Sciences Innovator Showcase
